Cargando…

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

OBJECTIVES: To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromboembolic events. METHODS: This analysis included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morand, Eric, Smolen, Josef S, Petri, Michelle, Tanaka, Yoshiya, Silk, Maria, Dickson, Christina, Meszaros, Gabriella, de la Torre, Inmaculada, Issa, Maher, Zhang, Hong, Dörner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445377/ https://www.ncbi.nlm.nih.gov/pubmed/37604638 http://dx.doi.org/10.1136/rmdopen-2023-003302

Ejemplares similares

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Role of P-glycoprotein on CD69(+)CD4(+) cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy
por: Tsujimura, Shizuyo, et al.
Publicado: (2017)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
por: You, Hanxiao, et al.
Publicado: (2023)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset
por: Alves, Pedro, et al.
Publicado: (2021)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
por: Mertz, Philippe, et al.
Publicado: (2022)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
por: Floris, Alberto, et al.
Publicado: (2022)

The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial
por: Keramiotou, Kyriaki, et al.
Publicado: (2020)

Increased risk of congenital malformations in offspring born to women with systemic lupus erythematosus in South Korea: a nationwide population-based study
por: Jung, Young Mi, et al.
Publicado: (2023)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
por: Zhang, Fengchun, et al.
Publicado: (2022)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus
por: AlE'ed, Ashwaq, et al.
Publicado: (2018)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01
por: Kawasaki, Aya, et al.
Publicado: (2023)

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
por: Calabrese, Cassandra, et al.
Publicado: (2023)

Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)
por: Reátegui-Sokolova, Cristina, et al.
Publicado: (2020)

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019)

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus
por: Nanes, Benjamin A, et al.
Publicado: (2020)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
por: Izmirly, Peter, et al.
Publicado: (2019)

Escaping the catch 22 of lupus anticoagulant testing
por: Vinholt, Pernille Just, et al.
Publicado: (2020)

Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus
por: Bao, Shengfang, et al.
Publicado: (2023)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dledpau4f4j6hg6cdb84r43il7